We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+22.21%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$303M
AUM Growth
-$35.4M
(-10%)
Cap. Flow
-$54.1M
Cap. Flow
% of AUM
-17.87%
Top 10 Holdings %
Top 10 Hldgs %
52.11%
Holding
73
New
15
Increased
24
Reduced
14
Closed
16
Top Buys
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$8.57M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$6.77M |
| 3 |
ONC
BeOne Medicines Ltd
ONC
|
+$5.18M |
| 4 |
AKRO
Akero Therapeutics
AKRO
|
+$3.9M |
| 5 |
Vir Biotechnology
VIR
|
+$3.77M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
+$8.48M |
| 2 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$8.4M |
| 3 |
Pfizer
PFE
|
+$8.16M |
| 4 |
Johnson & Johnson
JNJ
|
+$7.75M |
| 5 |
TG Therapeutics
TGTX
|
+$7.1M |
Sector Composition
| 1 | Healthcare | 91.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
26
DELISTED
Alpine Immune Sciences Inc
ALPN
| $3.57M | 1.18% |
347,432
+147,432
| +74% | +$1.33M |
|
|
JBIO
27
Jade Biosciences
JBIO
$1.27B
| $3.45M | 1.14% |
5,748
+34
| +0.6% | +$21.7K |
|
28
Zentalis Pharmaceuticals
ZNTL
$364M
| $2.82M | 0.93% |
+100,000
| New | +$2.4M |
|
|
KRTX
29
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $2.71M | 0.89% |
12,500
-5,000
| -29% | -$1.07M |
|
30
Tarsus Pharmaceuticals
TARS
$2.61B
| $2.71M | 0.89% |
150,000
+70,000
| +88% | +$1.11M |
|
|
FOLD
31
DELISTED
Amicus Therapeutics
FOLD
| $2.51M | 0.83% |
200,000
-275,000
| -58% | -$3.26M |
|
|
ATXS
32
DELISTED
Astria Therapeutics
ATXS
| $2.5M | 0.83% |
300,173
-149,827
| -33% | -$1.73M |
|
33
uniQure
QURE
$2.77B
| $2.46M | 0.81% |
215,000
-160,000
| -43% | -$3.03M |
|
34
Krystal Biotech
KRYS
$10.5B
| $2.35M | 0.78% |
+20,000
| New | +$2.04M |
|
|
VRNA
35
DELISTED
Verona Pharma
VRNA
| $2.33M | 0.77% |
+110,000
| New | +$2.35M |
|
36
Phathom Pharmaceuticals
PHAT
$873M
| $2.21M | 0.73% |
+154,250
| New | +$1.78M |
|
|
FUSN
37
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $1.93M | 0.64% |
412,699
+62,699
| +18% | +$271K |
|
|
IMGN
38
DELISTED
Immunogen Inc
IMGN
| $1.89M | 0.62% |
100,000
-24,977
| -20% | -$295K |
|
39
PMV Pharmaceuticals
PMVP
$71.5M
| $1.76M | 0.58% |
+280,981
| New | +$1.47M |
|
|
WHWK
40
Whitehawk Therapeutics
WHWK
$192M
| $1.71M | 0.56% |
250,000
+100,000
| +67% | +$777K |
|
41
Arcus Biosciences
RCUS
$3.44B
| $1.52M | 0.5% |
75,000
| – | – |
|
42
Rocket Pharmaceuticals
RCKT
$376M
| $1.49M | 0.49% |
+75,000
| New | +$1.52M |
|
43
BioCryst Pharmaceuticals
BCRX
$2.36B
| $1.41M | 0.46% |
200,000
-75,000
| -27% | -$602K |
|
|
MORF
44
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $1.15M | 0.38% |
+20,000
| New | +$1.04M |
|
|
INBX
45
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $909K | 0.3% |
+35,000
| New | +$817K |
|
46
CALL
BioXcel Therapeutics
BTAI
$27.4M
| $866K | 0.29% |
+8,125
| New | +$2.71M |
|
|
SWTX
47
DELISTED
SpringWorks Therapeutics
SWTX
| $723K | 0.24% |
27,578
| – | – |
|
48
BridgeBio Pharma
BBIO
$15.9B
| $722K | 0.24% |
42,000
+17,000
| +68% | +$256K |
|
|
RNAM
49
DELISTED
Avidity Biosciences
RNAM
| $721K | 0.24% |
65,000
-60,000
| -48% | -$753K |
|
50
Iovance Biotherapeutics
IOVA
$2.23B
| $704K | 0.23% |
100,000
-900,000
| -90% | -$6.44M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Ghost Tree Capital held 73 positions worth $303M, down 10% from $338M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Ghost Tree Capital withdrew a net $54.1M in Q2 2023, closing 16 positions and reducing 14 holdings. Its most notable exit was CTI BioPharma Corp. (DE) Common Stock, an estimated $8.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 78% a quarter earlier.
Against the trend, Ghost Tree Capital opened a new position in BeOne Medicines Ltd worth $4.01M.
- Ghost Tree Capital's largest Q2 2023 buy was BeOne Medicines Ltd: 22,500 shares worth $4.01M.
- Ghost Tree Capital added most to Revance Therapeutics, Inc. in Q2 2023, an estimated $8.57M increase.
- Ghost Tree Capital's biggest Q2 2023 reduction was Axsome Therapeutics, cutting an estimated $8.48M.
- Ghost Tree Capital fully exited CTI BioPharma Corp. (DE) Common Stock in Q2 2023, selling an estimated $8.4M.
- Ghost Tree Capital's ten largest holdings make up 52% of its $303M portfolio in Q2 2023.
- Ghost Tree Capital opened 15 new positions and closed 16 in Q2 2023.
- Ghost Tree Capital's portfolio value fell 10% quarter-over-quarter to $303M.
Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.